Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

	Three Months Ended March 31, 2025
		Products & Healthcare Services		Patient Direct		Consolidated
Net revenue	$	1,958,164	$	673,884	$	2,632,048
Cost of goods sold		1,751,393		354,642
Distribution, selling and administrative expenses		203,517		258,835
Other operating expense, net		2,101		266
Segment income	$	1,153	$	60,141		61,294
Acquisition-related charges and intangible amortization						(29,674)
Exit and realignment charges, net						(31,226)
Litigation and related charges (1)						(270)
Operating income					$	124
Capital expenditures	$	17,716	$	46,958	$	64,674

(1) Litigation and related charges includes settlement costs and related fees of legal matters within our Patient Direct Segment, which do not occur in the ordinary course of our business and are inherently unpredictable in timing and amount. These charges are reported within Other operating expense, net in our Statements of Operations for the three months ended March 31, 2025.

	Three Months Ended March 31, 2024
		Products & Healthcare Services		Patient Direct		Consolidated
Net revenue	$	1,974,837	$	637,843	$	2,612,680
Cost of goods sold		1,738,900		338,251
Distribution, selling and administrative expenses		224,081		253,532
Other operating expense, net		370		181
Segment income	$	11,486	$	45,879		57,365
Acquisition-related charges and intangible amortization						(20,313)
Exit and realignment charges, net						(27,356)
Operating income					$	9,696
Capital expenditures	$	8,250	$	41,158	$	49,408

	Three Months Ended
	March 31,
		2025		2024
Share-based compensation:
Products & Healthcare Services	$	4,068	$	4,769
Patient Direct		2,530		1,407
Other (1)		330		690
Consolidated share-based compensation:	$	6,928	$	6,866
Depreciation and amortization:
Products & Healthcare Services	$	10,833	$	11,547
Patient Direct		35,334		36,465
Intangible amortization		13,785		20,289
Other (2)		1,201		5,794
Consolidated depreciation and amortization:	$	61,153	$	74,095

(1) Other share-based compensation expense is captured within exit and realignment charges, net or acquisition-related charges and intangible amortization for the three months ended March 31, 2025 and 2024.

(2) Other depreciation and amortization expense is captured within exit and realignment charges, net for the three months ended March 31, 2025 and 2024.

Schedule of Consolidated Total Assets

	March 31, 2025		December 31, 2024
Total assets:
Products & Healthcare Services	$	2,630,037	$	2,429,513
Patient Direct		2,166,951		2,177,261
Segment assets		4,796,988		4,606,774
Cash and cash equivalents		59,436		49,382
Consolidated total assets	$	4,856,424	$	4,656,156

Schedule of Financial Information by Geographic Area

	Three Months Ended
	March 31,
	2025		2024
Net revenue:
United States	$	2,580,716	$	2,550,610
International		51,332		62,070
Consolidated net revenue	$	2,632,048	$	2,612,680